Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

被引：0
|
作者：
Chris Skedgel
Daniel Rayson
Tallal Younis
机构：
[1] University of East Anglia,Norwich Medical School
[2] Capital Health,Atlantic Clinical Cancer Research Unit
[3] Capital Health,Department of Medicine
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Breast cancer; Febrile neutropenia; Granulocyte colony-stimulating factors; Economic evaluation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：387 / 394
页数：7
相关论文
共 50 条
  • [31] Febrile neutropenia prophylaxis with short- and long-acting granulocyte colony-stimulating factors during treatment of solid tumours
    Kwinta, Lukasz
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (01): : 9 - 13
  • [32] Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer
    Calip, Gregory S.
    Malmgren, Judith A.
    Lee, Wan-Ju
    Schwartz, Stephen M.
    Kaplan, Henry G.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (01) : 133 - 143
  • [33] Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models
    Fust, Kelly
    Parthan, Anju
    Maschio, Michael
    Gu, Qing
    Li, Xiaoyan
    Lyman, Gary H.
    Tzivelekis, Spiros
    Villa, Guillermo
    Weinstein, Milton C.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (01) : 39 - 52
  • [34] Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
    Baig, Hassam
    Somlo, Barbara
    Eisen, Melissa
    Stryker, Scott
    Bensink, Mark
    Morrow, Phuong K.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (07) : 1576 - 1585
  • [35] Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy
    Bennett, Charles L.
    Djulbegovic, Benjamin
    Norris, LeAnn B.
    Armitage, James O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (12) : 1131 - 1139
  • [36] Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data
    Rastogi, Shruti
    Shukla, Shatrunajay
    Sharma, Arvind Kumar
    Sarwat, Maryam
    Srivastava, Pranay
    Katiyar, Tridiv
    Kalaiselvan, Vivekanandan
    Singh, Gyanendra Nath
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 395
  • [37] Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer
    Lapidari, Pietro
    Gbenou, Arnauld
    Havas, Julie
    Martin, Elise
    Pistilli, Barbara
    Martin, Anne-Laure
    Everhard, Sibille
    Coutant, Charles
    Cottu, Paul
    Lesur, Anne
    Lerebours, Florence
    Tredan, Olivier
    Vanlemmens, Laurence
    Jouannaud, Christelle
    Levy, Christelle
    Rigal, Olivier
    Fournier, Marion
    Andre, Fabrice
    Vaz-Luis, Ines
    Di Meglio, Antonio
    BREAST, 2021, 57 : 43 - 48
  • [38] The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
    Li Wang
    Onur Baser
    Lucie Kutikova
    John H. Page
    Richard Barron
    Supportive Care in Cancer, 2015, 23 : 3131 - 3140
  • [39] Suboptimal Duration of Granulocyte Colony stimulating Factor Use and Chemotherapy-induced Neutropenia in Women Diagnosed With Breast Cancer
    Lin, Wan-Ting
    Wen, Yu-Wen
    Chien, Chun-Ru
    Gau, Churn-Shiouh
    Chiang, Shao C.
    Hsiao, Fei-Yuan
    CLINICAL THERAPEUTICS, 2014, 36 (09) : 1287 - 1294
  • [40] Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer
    Griffiths R.I.
    Barron R.L.
    Gleeson M.L.
    Danese M.D.
    Ohagan A.
    Chia V.M.
    Legg J.C.
    Lyman G.H.
    PharmacoEconomics, 2012, 30 (2) : 103 - 118
12345